Pell Bio-Med Technology Co., Ltd. (TPE:6949)

Market Cap	37.07B +393.3%
Revenue (ttm)	31.42M +60.1%
Net Income	-423.94M
EPS	-7.23
Shares Out	64.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	152,434
Average Volume	265,420
Open	562.00
Previous Close	577.00
Day's Range	557.00 - 579.00
52-Week Range	105.50 - 758.00
Beta	0.60
RSI	48.40
Earnings Date	Mar 13, 2026

About Pell Bio-Med Technology

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen receptor T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is also involved in the phase 1/2 multicenter study to evaluate the safety and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6949

Financial Performance

In 2025, Pell Bio-Med Technology's revenue was 31.42 million, an increase of 60.07% compared to the previous year's 19.63 million. Losses were -423.94 million, 8.87% more than in 2024.